Amundi Pioneer Asset Management Inc. Takes $157,000 Position in Acceleron Pharma Inc (NASDAQ:XLRN)

Amundi Pioneer Asset Management Inc. acquired a new stake in shares of Acceleron Pharma Inc (NASDAQ:XLRN) during the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor acquired 3,600 shares of the biopharmaceutical company’s stock, valued at approximately $157,000.

A number of other institutional investors also recently modified their holdings of the stock. BlackRock Inc. lifted its position in Acceleron Pharma by 1.9% during the fourth quarter. BlackRock Inc. now owns 4,428,894 shares of the biopharmaceutical company’s stock valued at $192,880,000 after purchasing an additional 81,002 shares during the period. Vanguard Group Inc. raised its position in Acceleron Pharma by 33.0% in the third quarter. Vanguard Group Inc. now owns 3,425,363 shares of the biopharmaceutical company’s stock worth $196,034,000 after acquiring an additional 849,608 shares during the period. Vanguard Group Inc raised its position in Acceleron Pharma by 33.0% in the third quarter. Vanguard Group Inc now owns 3,425,363 shares of the biopharmaceutical company’s stock worth $196,034,000 after acquiring an additional 849,608 shares during the period. Westfield Capital Management Co. LP raised its position in Acceleron Pharma by 9.2% in the fourth quarter. Westfield Capital Management Co. LP now owns 1,292,713 shares of the biopharmaceutical company’s stock worth $56,298,000 after acquiring an additional 108,405 shares during the period. Finally, Geode Capital Management LLC raised its position in Acceleron Pharma by 7.7% in the fourth quarter. Geode Capital Management LLC now owns 453,463 shares of the biopharmaceutical company’s stock worth $19,748,000 after acquiring an additional 32,521 shares during the period. Institutional investors own 84.67% of the company’s stock.

Several research firms have weighed in on XLRN. Zacks Investment Research upgraded shares of Acceleron Pharma from a “hold” rating to a “buy” rating and set a $46.00 price target on the stock in a research report on Friday. Barclays downgraded shares of Acceleron Pharma from an “overweight” rating to an “equal weight” rating and decreased their price target for the stock from $54.00 to $45.00 in a research report on Friday. CIBC reiterated an “outperform” rating on shares of Acceleron Pharma in a research report on Monday, April 22nd. Oppenheimer restated an “outperform” rating on shares of Acceleron Pharma in a research report on Monday, April 22nd. Finally, ValuEngine downgraded shares of Acceleron Pharma from a “strong-buy” rating to a “buy” rating in a research report on Thursday, April 18th. One analyst has rated the stock with a sell rating, five have given a hold rating and ten have issued a buy rating to the company’s stock. The stock has an average rating of “Buy” and a consensus price target of $57.60.

In related news, CFO Kevin F. Mclaughlin sold 648 shares of the firm’s stock in a transaction on Tuesday, April 2nd. The shares were sold at an average price of $48.02, for a total transaction of $31,116.96. Following the completion of the transaction, the chief financial officer now directly owns 42,279 shares of the company’s stock, valued at $2,030,237.58. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, CEO Habib J. Dable sold 7,460 shares of the firm’s stock in a transaction on Tuesday, April 9th. The shares were sold at an average price of $44.60, for a total transaction of $332,716.00. Following the transaction, the chief executive officer now directly owns 76,754 shares of the company’s stock, valued at $3,423,228.40. The disclosure for this sale can be found here. Insiders have sold 23,730 shares of company stock valued at $1,060,959 over the last ninety days. 2.50% of the stock is currently owned by corporate insiders.

Shares of XLRN stock traded up $1.00 on Friday, hitting $41.49. 273,316 shares of the stock traded hands, compared to its average volume of 450,521. The company has a market capitalization of $2.19 billion, a price-to-earnings ratio of -16.02 and a beta of 1.32. Acceleron Pharma Inc has a 52 week low of $32.53 and a 52 week high of $59.59.

Acceleron Pharma (NASDAQ:XLRN) last posted its earnings results on Wednesday, February 27th. The biopharmaceutical company reported ($0.75) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.67) by ($0.08). The company had revenue of $3.80 million for the quarter, compared to analysts’ expectations of $3.21 million. Acceleron Pharma had a negative net margin of 849.62% and a negative return on equity of 36.63%. The business’s revenue was up 2.7% on a year-over-year basis. During the same period in the previous year, the business posted ($0.62) earnings per share. As a group, equities analysts expect that Acceleron Pharma Inc will post -2.15 earnings per share for the current year.

TRADEMARK VIOLATION NOTICE: This story was first published by Baseball Daily News and is the sole property of of Baseball Daily News. If you are viewing this story on another site, it was illegally stolen and reposted in violation of U.S. and international copyright & trademark laws. The original version of this story can be read at https://www.baseballdailydigest.com/news/2019/05/04/amundi-pioneer-asset-management-inc-takes-position-in-acceleron-pharma-inc-xlrn.html.

Acceleron Pharma Profile

Acceleron Pharma Inc, a clinical stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics to treat serious and rare diseases. Its therapeutic candidates include luspatercept, which is in Phase III clinical trials for the treatment of myelodysplastic syndromes and beta-thalassemia; Phase II clinical trials for the treatment of patients with transfusion-dependent beta-thalassemia and myelofibrosis.

Recommended Story: Trading Options- What is a Strangle?

Institutional Ownership by Quarter for Acceleron Pharma (NASDAQ:XLRN)

Receive News & Ratings for Acceleron Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Acceleron Pharma and related companies with MarketBeat.com's FREE daily email newsletter.